Safety and efficacy of interferon-α in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy

Kimiyoshi Arimura, Masanori Nakagawa, Shuji Izumo, Koichiro Usuku, Yasuto Itoyama, Jun-Ichi Kira, Mitsuhiro Osame

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A postmarketing surveillance study was undertaken to investigate the safety and efficacy of interferon-α for human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) under routine treatment conditions. A total of 273 cases from 91 medical institutions were registered into the survey. So far, 167 cases had been evaluated for safety and 152 for efficacy. The efficacy evaluation was rated based on clinical symptoms of HAM. Efficacy ratio (rate of patients assessed as "modest to markedly improved" and "mildly improved") at 4 weeks was 66.2%. Factors that significantly affected efficacy ratio at 4 weeks was initial Osame's motor disability score (OMDS) before interferon-α therapy and duration and stage of illness. Sustained improvement of OMDS for at least 5 months after stopping interferon-α was observed in 11 of 30 patients (36.7%). A total of 536 adverse drug reactions (ADRs) occurred in 146 patients, 46 of which were serious. Because some of these ADRs occurred late, it is necessary to watch out for them during long-term treatment.

Original languageEnglish
Pages (from-to)364-372
Number of pages9
JournalJournal of NeuroVirology
Volume13
Issue number4
DOIs
Publication statusPublished - Jul 1 2007

Fingerprint

Tropical Spastic Paraparesis
Interferons
Drug-Related Side Effects and Adverse Reactions
T-Lymphocytes
Safety
Human T-lymphotropic virus 1
Spinal Cord Diseases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this

Safety and efficacy of interferon-α in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy. / Arimura, Kimiyoshi; Nakagawa, Masanori; Izumo, Shuji; Usuku, Koichiro; Itoyama, Yasuto; Kira, Jun-Ichi; Osame, Mitsuhiro.

In: Journal of NeuroVirology, Vol. 13, No. 4, 01.07.2007, p. 364-372.

Research output: Contribution to journalArticle

Arimura, Kimiyoshi ; Nakagawa, Masanori ; Izumo, Shuji ; Usuku, Koichiro ; Itoyama, Yasuto ; Kira, Jun-Ichi ; Osame, Mitsuhiro. / Safety and efficacy of interferon-α in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy. In: Journal of NeuroVirology. 2007 ; Vol. 13, No. 4. pp. 364-372.
@article{006e322ae3e444a6b192b6b5d76bb311,
title = "Safety and efficacy of interferon-α in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy",
abstract = "A postmarketing surveillance study was undertaken to investigate the safety and efficacy of interferon-α for human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) under routine treatment conditions. A total of 273 cases from 91 medical institutions were registered into the survey. So far, 167 cases had been evaluated for safety and 152 for efficacy. The efficacy evaluation was rated based on clinical symptoms of HAM. Efficacy ratio (rate of patients assessed as {"}modest to markedly improved{"} and {"}mildly improved{"}) at 4 weeks was 66.2{\%}. Factors that significantly affected efficacy ratio at 4 weeks was initial Osame's motor disability score (OMDS) before interferon-α therapy and duration and stage of illness. Sustained improvement of OMDS for at least 5 months after stopping interferon-α was observed in 11 of 30 patients (36.7{\%}). A total of 536 adverse drug reactions (ADRs) occurred in 146 patients, 46 of which were serious. Because some of these ADRs occurred late, it is necessary to watch out for them during long-term treatment.",
author = "Kimiyoshi Arimura and Masanori Nakagawa and Shuji Izumo and Koichiro Usuku and Yasuto Itoyama and Jun-Ichi Kira and Mitsuhiro Osame",
year = "2007",
month = "7",
day = "1",
doi = "10.1080/13550280701397627",
language = "English",
volume = "13",
pages = "364--372",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Safety and efficacy of interferon-α in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy

AU - Arimura, Kimiyoshi

AU - Nakagawa, Masanori

AU - Izumo, Shuji

AU - Usuku, Koichiro

AU - Itoyama, Yasuto

AU - Kira, Jun-Ichi

AU - Osame, Mitsuhiro

PY - 2007/7/1

Y1 - 2007/7/1

N2 - A postmarketing surveillance study was undertaken to investigate the safety and efficacy of interferon-α for human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) under routine treatment conditions. A total of 273 cases from 91 medical institutions were registered into the survey. So far, 167 cases had been evaluated for safety and 152 for efficacy. The efficacy evaluation was rated based on clinical symptoms of HAM. Efficacy ratio (rate of patients assessed as "modest to markedly improved" and "mildly improved") at 4 weeks was 66.2%. Factors that significantly affected efficacy ratio at 4 weeks was initial Osame's motor disability score (OMDS) before interferon-α therapy and duration and stage of illness. Sustained improvement of OMDS for at least 5 months after stopping interferon-α was observed in 11 of 30 patients (36.7%). A total of 536 adverse drug reactions (ADRs) occurred in 146 patients, 46 of which were serious. Because some of these ADRs occurred late, it is necessary to watch out for them during long-term treatment.

AB - A postmarketing surveillance study was undertaken to investigate the safety and efficacy of interferon-α for human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) under routine treatment conditions. A total of 273 cases from 91 medical institutions were registered into the survey. So far, 167 cases had been evaluated for safety and 152 for efficacy. The efficacy evaluation was rated based on clinical symptoms of HAM. Efficacy ratio (rate of patients assessed as "modest to markedly improved" and "mildly improved") at 4 weeks was 66.2%. Factors that significantly affected efficacy ratio at 4 weeks was initial Osame's motor disability score (OMDS) before interferon-α therapy and duration and stage of illness. Sustained improvement of OMDS for at least 5 months after stopping interferon-α was observed in 11 of 30 patients (36.7%). A total of 536 adverse drug reactions (ADRs) occurred in 146 patients, 46 of which were serious. Because some of these ADRs occurred late, it is necessary to watch out for them during long-term treatment.

UR - http://www.scopus.com/inward/record.url?scp=34548606973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548606973&partnerID=8YFLogxK

U2 - 10.1080/13550280701397627

DO - 10.1080/13550280701397627

M3 - Article

C2 - 17849320

AN - SCOPUS:34548606973

VL - 13

SP - 364

EP - 372

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 4

ER -